Suppr超能文献

芳香酶抑制剂对乳腺磁共振成像中背景实质强化和纤维腺体组织量的影响。

Effect of aromatase inhibitors on background parenchymal enhancement and amount of fibroglandular tissue at breast MR imaging.

机构信息

Department of Radiology, Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

出版信息

Radiology. 2012 Sep;264(3):670-8. doi: 10.1148/radiol.12112669. Epub 2012 Jul 6.

Abstract

PURPOSE

To evaluate whether treatment with an aromatase inhibitor (AI) influences background parenchymal enhancement (BPE) or amount of fibroglandular tissue (FGT) at breast magnetic resonance (MR) imaging in postmenopausal women with prior history of breast cancer.

MATERIALS AND METHODS

A waiver of authorization and patient consent was granted by the institutional review board for this HIPAA-compliant retrospective study. Postmenopausal women with breast cancer and MR imaging findings of the contralateral unaffected breast, before and during 6-12 months of AI treatment (anastrozole, letrozole, or exemestane), between August 1999 and June 2010 were retrospectively identified (n = 149). Two readers performed blinded side-by-side comparison of BPE and MR imaging-depicted FGT before and during treatment. BPE and FGT were classified as the same or greater on one of the two MR studies and by using categorical scales: minimal, mild, moderate, or marked for BPE and fatty, scattered, heterogeneously dense, or dense for FGT. Consensus was reached in cases of disagreement. The sign test was used to conduct a side-by-side comparison of BPE and FGT before and during AI treatment.

RESULTS

A decrease in BPE occurred in 33.9% (37 of 109) of women during anastrozole treatment, while an increase occurred in only one (P < .0001); 28 of 37 decreases resulted in a category change of BPE. A decrease in MR imaging-depicted FGT occurred in 5.5% (six of 109) of women, while no increases occurred (P = .031). During letrozole treatment, a decrease in BPE occurred in 46% (15 of 33), while an increase occurred in one woman (P = .0003); a decrease in FGT occurred in only one woman, and no increases occurred. Similar results were seen when women also undergoing chemotherapy were excluded. Only seven women were treated with exemestane.

CONCLUSION

Treatment with 6-12 months of anastrozole or letrozole was associated with decreases in BPE, which occurred in a greater proportion of women than decreases in FGT.

摘要

目的

评估芳香化酶抑制剂 (AI) 治疗是否会影响既往乳腺癌病史的绝经后女性的乳腺磁共振 (MR) 成像中的背景实质强化 (BPE) 或纤维腺体组织 (FGT) 量。

材料与方法

本 HIPAA 合规性回顾性研究获得了机构审查委员会的豁免授权和患者同意。回顾性确定了 1999 年 8 月至 2010 年 6 月间,在接受阿那曲唑、来曲唑或依西美坦治疗的 6-12 个月期间,双侧未受影响乳房的 MR 成像结果有乳腺癌的绝经后女性(n = 149)。两名读者对治疗前后的 BPE 和 MR 成像显示的 FGT 进行了盲法并排比较。BPE 和 FGT 通过以下两种方式之一被归类为相同或更大:在两次 MR 研究中的一次和使用分类量表:最小、轻度、中度或明显的 BPE 和脂肪、散在、异质密集或密集的 FGT。在有分歧的情况下达成共识。符号检验用于比较 AI 治疗前后的 BPE 和 FGT。

结果

在接受阿那曲唑治疗的 33.9%(109 例中的 37 例)女性中,BPE 下降,而只有 1 例增加(P <.0001);37 次下降中有 28 次导致 BPE 类别发生变化。在 109 例女性中,有 5.5%(6 例)的 FGT 减少,而没有增加(P =.031)。在接受来曲唑治疗的女性中,有 46%(33 例中的 15 例)的 BPE 下降,而有 1 例增加(P =.0003);FGT 仅减少 1 例,无增加。排除同时接受化疗的女性后,结果相似。仅有 7 名女性接受依西美坦治疗。

结论

接受 6-12 个月的阿那曲唑或来曲唑治疗与 BPE 下降相关,与 FGT 下降相比,BPE 下降发生在更多女性中。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验